Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies. The study aims to assess the safety and efficacy of ABBV-932 when added to existing antidepressant therapies in adults with generalized anxiety disorder (GAD) who have not responded adequately to standard treatments.
The intervention being tested is ABBV-932, an investigational oral drug intended to enhance the effectiveness of antidepressant therapies in treating GAD. Participants will receive either ABBV-932 or a placebo alongside their current antidepressant regimen.
This study is interventional, randomized, and uses a parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on February 21, 2025, with the latest update submitted on August 28, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
For investors, this study could significantly impact AbbVie’s stock performance if ABBV-932 proves effective, potentially positioning the company as a leader in the GAD treatment market. The study’s outcome may also influence investor sentiment and competitive dynamics within the pharmaceutical industry.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.